
Physician office payment for biosimilars in Medicare Part B 2022
This statistic shows a hypothetical example of physician office payments for biosimilars in Medicare Part B as of 2022. The wholesale acquisition cost (WAC) for the reference drug would be one thousand U.S. dollars, while the WAC for biosimilar A would be 200 dollars lower.